Guangzhou Ruiling Pharmaceutical

Guangzhou Ruiling Pharmaceutical Co., Ltd. is a clinical-stage biotechnology company based in Guangzhou, China, and a subsidiary of Shanghai Regenelead Therapies (also known as Shanghai Ruihongdi Pharmaceutical), which is part of the Jiangsu Hengrui Pharmaceuticals group. Established in 2024, the company focuses on developing advanced therapeutic products using mRNA and gene therapy platforms. Its lead candidate, RGL-2102, is an mRNA-based therapy encoding Hepatocyte Growth Factor (HGF) currently in Phase 2/3 clinical trials for diabetic foot ulcers and Phase 2 for critical limb ischemia. The company is also advancing RGL-232, a therapeutic mRNA vaccine targeting multiple KRAS mutations, which is in Phase 1 clinical development for advanced solid tumors. Guangzhou Ruiling leverages the extensive research and manufacturing capabilities of its parent organizations to address significant unmet needs in oncology, cardiovascular, and metabolic diseases.